Association between HTLV-I Infection and Chronic Lupoid Leishmaniasis

Authors

1 Cutaneous Leishmanaisis Research Center,Ghaem Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

2 HTLV-I Foundation, Immunology Department, Mashhad University of Medical Sciences, Mashhad, Iran

3 Department of Internal Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

4 Department of Social Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Keywords


Lupi O. Protozoa and worms. In: Bolognia JL, Jorizzo JL, Rapini
RO, Schaffer JV, editors. Dermatology. 2th ed. Spain: Mosby Elsevier;
2008. Vol 1.p.1263-1290.
2. Oumeish OY. Cutaneous leishmaniasis: a historical perspective.
Clin Dermatol 1999 ;17:249-254.
3. Asilian A, Iraji F, Hedaiti HR, Siadat AH, Enshaieh S. Carbon dioxide
laser for the treatment of lupoid cutaneous leishmaniasis
(LCL): a case series of 24 patients. Dermatol Online J 2006; 12:3.
4. Vega Lopez F, Hay RJ. Parasitic worms and protozoa. In: Burns T,
Breathnach S, Cox N, Griffiths C, editors. Rook’s text book of dermatology.
8 th ed.USA: Blackwell Science; 2010. Vol 2 p.37.1-44.
5. Ajdary S, Alimohammadian MH, Eslami MB, Kemp K, Kharazmi
A. Comparison of the immune profile of nonhealing cutaneous
Leishmaniasis patients with those with active lesions and those
who have recovered from infection. Infect Immun 2000; 68:1760-
1764.
6. Stefanidou MP, Antoniou M, Koutsopoulos AV, Neofytou YT,
Krasagakis K, Kruger-Krasagakis S,
et al.
A rare case of leishmaniasisrecidivacutis
evolving for 31 years caused by Leishmaniatropica.
 
Int J Dermatol 2008; 47:588-589.
 
7. Rafatpanah H, Hedayati-Moghaddam MR, Fathimoghadam F,
 
Bidkhori HR, Shamsian SK, Ahmadi S,
 
 
et al
. High prevalence of
HTLV-I infection in Mashhad, Northeast Iran: a population-based
 
seroepidemiologysurvey. J Clin Virol 2011; 52:172-176.
 
8. Nakada K, Yamaguchi K, Furugen S, Nakasone T, Nakasone K, Oshiro
 
Y,
 
 
et al.
Monoclonal integration of HTLV-I proviral DNA in
patients with strongyloidiasis. Int J Cancer 1987; 40:145-148.
 
9. Goncalves DU, Guedes AC, Proietti AB, Martins ML, Proietti FA,
 
Lambertucci JR,
 
 
et al.
Dermatologic lesions in asymptomatic
blood donors seropositive for human T cell lymphotropic virus
 
type-1. Am J Trop Med Hyg 2003; 68:562-565.
 
10. Lenzi ME, Cuzzi-Maya T, Oliveira AL, Andrada-Serpa MJ, Araujo AQ.
 
Dermatological findings of human T lymphotropic virus type 1
 
(HTLV-I)-associated myelopathy/tropical spastic paraparesis.
 
Clin Infect Dis 2003; 36:507-513.
 
 
283
HTLV-I Infection and Chronic Lupoid Leishmaniasis Pezeshkpoor F et al
Iran J Basic Med Sci; Vol. 16, No. 3, Mar 2013
11. Kuroda Y, Takashima H. Impairment of cell –mediated immune
response in HTLV-I associated myelopathy. J Neurol Sci 1990;
100:211-216.
12. Lenis AM, Blank A, Valderrama L, Saravia NG. Relationship between
the human T-lymphotropic virus type 1 infection and
clinical manifestations of tegumentary leishmaniasis in the Colombian
Pacific Coast. Mem Inst Oswaldo Cruz 1999; 94:19-20.
13. Meymandi S, Dabiri S, Shamsi-Meymandi M, Nikpour H, Kharazmi
A. Immunophenotypic pattern and cytokine profiles of dry
type cutaneous leishmaniasis. Arch Iran Med 2009; 12:371-376.